ALINT.PA stock surges 15% in pre-market as volume spikes on May 13

IntegraGen SA (ALINT.PA) is making waves in pre-market trading on EURONEXT today. The French biotechnology company’s stock surged 15.13% to €0.274, driven by exceptional trading volume that reached 43,277 shares—more than 3 times the average daily volume. This sharp move reflects strong investor interest in the genomics specialist, which provides DNA sequencing, transcriptomics, and clinical research services. Trading in EUR on Europe’s primary exchange, ALINT.PA stock has captured attention as a high-volume mover during this morning’s session.

ALINT.PA Stock Performance and Price Action

IntegraGen SA opened today at €0.25 and quickly climbed to a session high of €0.274, marking the day’s peak. The stock gained €0.036 from yesterday’s close of €0.238, translating to that impressive 15.13% jump. Over the past five days, ALINT.PA stock has rallied 69.14%, and year-to-date performance stands at a remarkable 106.02% gain.

However, the longer-term picture tells a different story. Over the past year, ALINT.PA stock has declined 55.07%, and the three-year performance shows a steeper 78.51% loss. The stock’s 52-week range spans from €0.115 (low) to €0.732 (high), indicating significant volatility. Today’s price sits well below the 50-day moving average of €0.178 and the 200-day average of €0.181, suggesting the stock remains under pressure on longer timeframes despite today’s strength.

Market Sentiment and Trading Activity

The exceptional volume surge today signals heightened investor engagement with ALINT.PA stock. Volume reached 43,277 shares compared to the average of 13,923, representing a relative volume multiplier of 3.11x. This spike indicates active buying interest, though it’s important to note that high volume alone doesn’t guarantee sustained momentum.

Technical indicators show mixed signals. The Relative Strength Index (RSI) stands at 78.75, indicating overbought conditions that typically precede pullbacks. The Money Flow Index (MFI) also reads 95.14, suggesting extreme buying pressure. Meanwhile, the Average True Range (ATR) of €0.02 reflects the stock’s typical daily volatility. Track ALINT.PA on Meyka for real-time updates on these technical developments and market sentiment shifts throughout the trading day.

Company Fundamentals and Financial Health

IntegraGen SA, headquartered in Évry, France, operates as a subsidiary of OncoDNA SA with 440 full-time employees. The company specializes in genomic services including transcriptomics, epigenomics, DNA sequencing, and NGS testing for cancer research. It also offers proprietary software tools like MERCURY for oncology interpretation and SIRIUS for sequencing data analysis.

Financially, the company faces challenges. The latest earnings per share (EPS) stands at -€0.04, reflecting ongoing losses. The price-to-earnings ratio is negative at -6.85, which occurs when companies report losses. Revenue per share totals €0.731, while the price-to-sales ratio of 0.36 suggests the stock trades at a discount to revenue. The market capitalization sits at approximately €1.81 million, making ALINT.PA a micro-cap stock with limited liquidity outside today’s spike.

Meyka AI Rating and Investment Perspective

Meyka AI rates ALINT.PA with a grade of B, reflecting a mixed outlook. The overall rating score of 62.82 translates to a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reveals contrasting signals: the company scores strongly on ROE metrics (Strong Buy recommendation) but shows weakness in DCF valuation, ROA, debt-to-equity, and PE ratios (all Strong Sell recommendations).

These grades are not guaranteed and we are not financial advisors. The biotechnology sector on EURONEXT has faced headwinds, with the Healthcare sector down 1.19% today. IntegraGen’s negative profitability metrics and micro-cap status present elevated risk for investors. The company’s next earnings announcement is scheduled for April 10, 2026, which may provide clarity on operational progress and cash burn rates.

Final Thoughts

IntegraGen SA (ALINT.PA) is experiencing a notable pre-market surge today with 15.13% gains and exceptional volume activity. While the short-term momentum is undeniable, investors should recognize the broader context: the stock remains deeply unprofitable, trades at micro-cap valuations, and shows significant long-term losses. The overbought technical indicators suggest caution about chasing today’s rally. Meyka AI’s HOLD rating reflects this balanced view—acknowledging some positive metrics while flagging serious profitability concerns. Traders monitoring ALINT.PA stock should watch for profit-taking as the session progresses and await upcoming earnings results for fundamental clarity.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.